Pacific Biosciences of California, or PacBio, lowered its 2026 revenue guidance to $155-$165 million from $165-$175 million, citing weaker instrument demand and a slower-than-expected transition to its SPRQ-Nx chemistry, even as clinical adoption grows. The company now expects cash-flow breakeven in 2028 instead of by the end of 2027, and reduced its 2026 non-GAAP gross-margin outlook to 35%-37%. In the second quarter, revenues fell 2% to $39 million, missing the Zacks Consensus Estimate by 4.2%, with instrument revenues down 9.9% to $12.8 million. However, clinical consumable shipments rose 67%, and EMEA revenues increased 52% to $14.4 million, while PacBio shipped 20 Revio systems, up from 15 a year earlier. The company expects restructuring to cut 2027 compensation-related expenses by about $15-$20 million, with additional annual savings as high-throughput platform development spending declines.
Pacific Biosciences of CaliforniaCut 2026 revenue guidance and delayed cash-flow breakeven to 2028.
Illumina Inc
Thermo Fisher Scientific Inc